Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
EMERYVILLE, Calif., Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 2:35 p.m. ET.
加利福尼亞州埃默裏維爾，2024年11月26日 /PRNewswire/ -- 德納維製藥公司（納斯達克：DVAX）是一家開發和商業化創新生物-疫苗的商業階段生物製藥公司，今天宣佈公司將於12月3日（星期二）下午2:35參加第七屆evercore HealthCONx會議。
The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at .
此次演講將進行網絡直播，可以通過公司網站「投資者」部分的「活動與演示」頁面訪問。
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018 adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit .
關於德納維製藥
德納維製藥是一家商業階段的生物製藥公司，開發和商業化創新生物-疫苗，以幫助保護世界免受傳染病的侵害。該公司有兩種商業產品，HEPLISAV-b生物-疫苗（乙型肝炎疫苗（重組）、佐劑），已在美國、歐盟和英國獲批准，用於預防18歲及以上成人感染所有已知亞型乙型肝炎病毒引起的感染，以及CpG 1018佐劑，目前用於HEPLISAV-b和多種佐劑COVID-19生物-疫苗。如需了解我們的上市產品和開發管道的更多信息，請訪問。
For Investors/Media:
Paul Cox
[email protected]
510-665-0499
對於投資者/媒體：
保羅·考克斯
[email protected]
510-665-0499
Nicole Arndt
[email protected]
510-665-7264
Nicole Arndt
[email protected]
510-665-7264
SOURCE Dynavax Technologies
SOURCE Dynavax Technologies
